| アブストラクト | 5-alpha reductase inhibitors (5alphaRIs) are effective for the treatment of benign prostatic hyperplasia (BPH). However, 5alphaRIs could lower levels of haemoglobin, increasing the risk of anaemia. The objective of this study was to compare the rate of anaemia between new users of 5alphaRIs and alpha-blockers in the UK. METHODS: We conducted a matched, active comparator, new-user cohort study using the Clinical Practice Research Datalink. The study population consisted of men aged >/=40 years with incident BPH who initiated 5alphaRIs between 1998 and 2019 and were matched 1:1 on propensity score to new users of alpha-blockers. Anaemia was defined by a measured haemoglobin <130 g/L. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for anaemia. RESULTS: Our study cohort included 9429 new users of 5alphaRIs and 9429 matched new users of alpha-blockers. Their median durations of follow-up were 136 days (interquartile range: 54-336 d) and 77 days (interquartile range: 58-236 d), respectively. A total of 2865 5alphaRIs users and 2407 alpha-blocker users developed incident anaemia, representing rates of 37.3 (95% CI: 33.6-41.3) and 42.0 (95% CI: 38.1-46.2) per 100 person-years, respectively. The use of 5alphaRIs was not associated with an increased risk of anaemia compared to the use of alpha-blockers (HR: 0.95, 95% CI: 0.90-1.00). Similarly, we did not observe an increased risk of mild, moderate, or severe anaemia. CONCLUSION: The use of 5alphaRIs was not associated with an increased risk of anaemia compared to the use of alpha-blockers among men with BPH. |
|---|
| ジャーナル名 | British journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2022/3/19 |
|---|
| 投稿者 | Ayele, Henok Tadesse; Douros, Antonios; Filion, Kristian B |
|---|
| 組織名 | Department of Epidemiology, Biostatistics, Occupational Health, McGill University;Montreal, Canada.;Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;Department of Medicine, McGill University, Montreal, Canada.;Institute of Clinical Pharmacology and Toxicology, Charite - Universitatsmedizin;Berlin, Berlin, Germany. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35301747/ |
|---|
